8-K
false 0001757898 0001757898 2023-07-27 2023-07-27 0001757898 us-gaap:CommonStockMember 2023-07-27 2023-07-27 0001757898 ste:M2.700SeniorNotesDue2031Member 2023-07-27 2023-07-27 0001757898 ste:M3.750SeniorNotesDue2051Member 2023-07-27 2023-07-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2023

 

 

STERIS plc

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-38848   98-1455064
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

70 Sir John Rogerson’s Quay
Dublin 2, Ireland
(Address of Principal Executive Offices)

+353 1 232 2000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Ordinary Shares. $0.001 par value   STE   New York Stock Exchange
2.700% Senior Notes due 2031   STE/31   New York Stock Exchange
3.750% Senior Notes due 2051   ST/51   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


ITEM 5.07.

Submission of Matters to a Vote of Security Holders.

At the 2023 Annual General Meeting of Shareholders (“Meeting”) of STERIS plc (the “Company”) held on July 27, 2023, shareholders voted on the matters specified below, with the final voting results as specified. According to the certified list of shareholders, there were 98,650,991 Ordinary Shares of the Company outstanding and entitled to vote at the Meeting. There were present at the Meeting, in person or by proxy, the holders of 91,717,850 Ordinary Shares or 92.97% of the outstanding Ordinary Shares of the Company, constituting a quorum.

 

1.

The shareholders elected the nominees named below to the board of directors of the Company (the “Board”), each for a one-year term, and the results of the vote were as follows:

 

Nominee

   Votes for      Votes
against
     Abstentions      Broker
non-votes
 

Esther M. Alegria

     87,930,589        166,648        69,798        3,550,815  

Richard C. Breeden

     83,412,606        4,674,581        79,848        3,550,815  

Daniel A. Carestio

     86,828,206        1,301,677        37,152        3,550,815  

Cynthia L. Feldmann

     78,692,106        5,944,870        3,530,059        3,550,815  

Christopher S. Holland

     87,150,387        932,962        83,686        3,550,815  

Dr. Jacqueline B. Kosecoff

     79,498,778        8,597,293        70,964        3,550,815  

Paul E. Martin

     86,306,636        1,785,736        74,663        3,550,815  

Dr. Nirav R. Shah

     87,034,737        1,007,908        124,390        3,550,815  

Dr. Mohsen M. Sohi

     83,787,674        4,300,162        79,199        3,550,815  

Dr. Richard M. Steeves

     87,059,127        1,031,717        76,191        3,550,815  

 

2.

The shareholders approved the proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2024 by the following votes:

 

Votes for

     83,026,435  

Votes against

     8,633,905  

Abstentions

     57,510  

 

3.

The shareholders approved the proposal to appoint Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law to hold office until the conclusion of the Company’s next Annual General Meeting by the following votes:

 

Votes for

     83,051,183  

Votes against

     8,608,501  

Abstentions

     58,166  

 

4.

The shareholders approved the proposal to authorize the Board of the Company or the Audit Committee of the Board to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s statutory auditor under Irish law by the following votes:

 

Votes for

     90,452,843  

Votes against

     1,215,360  

Abstentions

     49,647  

 

5.

The shareholders approved the proposal to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 7, 2023, by the following votes:

 

Votes for

     81,238,272  

Votes against

     6,841,234  

Abstentions

     87,529  

Broker non-votes

     3,550,815  

 


6.

The shareholders approved “one-year” for the proposal to approve, on a non-binding advisory basis whether the non-binding advisory vote on named executive officer compensation should be held every one, two or three years, by the following votes:

 

One Year

     87,154,402  

Two Years

     46,103  

Three Years

     923,796  

Abstentions

     42,734  

Broker non-votes

     3,550,815  

 

7.

The shareholders approved the proposal to the renewal of the Board’s authority to issue authorized but unissued shares under Irish law, by the following votes:

 

Votes for

     89,904,671  

Votes against

     1,766,723  

Abstentions

     46,456  

 

8.

The shareholders approved the proposal to approve the renewal of the Board’s authority to opt-out of statutory pre-emption rights under Irish law regarding the issuance of shares for cash, by the following votes:

 

Votes for

     85,582,812  

Votes against

     5,955,437  

Abstentions

     179,601  

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

STERIS plc
By  

/s/ J. Adam Zangerle

  J. Adam Zangerle
  Senior Vice President, General Counsel and Company Secretary

Dated: July 27, 2023

Shareholder Tools